Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

The new rule was contained within a larger proposal to ensure contraceptive coverage in the face of Republican attacks.

“With low uptake of PrEP among the communities most impacted by HIV, this insurance coverage requirement with ... healthcare ...

Unlike oral PrEP treatments, which are taken daily, the drug is administered at six-month intervals and is the longest acting injectable produced to date. In a late-stage trial, lenacapavir reduced ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...